論文

査読有り
2019年2月22日

is a therapeutic target in SPG4-related hereditary spastic paraplegia human neurons.

Clinical Science
  • Fumiko Nakazeki
  • ,
  • Itaru Tsuge
  • ,
  • Takahiro Horie
  • ,
  • Keiko Imamura
  • ,
  • Kayoko Tsukita
  • ,
  • Akitsu Hotta
  • ,
  • Osamu Baba
  • ,
  • Yasuhide Kuwabara
  • ,
  • Tomohiro Nishino
  • ,
  • Tetsushi Nakao
  • ,
  • Masataka Nishiga
  • ,
  • Hitoo Nishi
  • ,
  • Yasuhiro Nakashima
  • ,
  • Yuya Ide
  • ,
  • Satoshi Koyama
  • ,
  • Masahiro Kimura
  • ,
  • Shuhei Tsuji
  • ,
  • Motoko Naitoh
  • ,
  • Shigehiko Suzuki
  • ,
  • Yuishin Izumi
  • ,
  • Toshitaka Kawarai
  • ,
  • Ryuji Kaji
  • ,
  • Takeshi Kimura
  • ,
  • Haruhisa Inoue
  • ,
  • Koh Ono

Vol.133
No.4
開始ページ
583
終了ページ
595
記述言語
英語
掲載種別
研究論文(大学,研究機関等紀要)
DOI
10.1042/CS20180980

in human neurons, via locked nucleic acid (LNA)-anti-miR ameliorated the pathological phenotype in hereditary spastic paraplegia (HSP)-SPG4 patient induced pluripotent stem cell (iPSC)-derived cortical neurons. Thus, miR-33a can be a potential therapeutic target for the treatment of HSP-SPG4.

リンク情報
DOI
https://doi.org/10.1042/CS20180980
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/30777884

エクスポート
BibTeX RIS